CoChat
Sign Up
Cited by 139Hormonal and reproductive studiesDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta‐analysis of randomized controlled clinical trials

Grossmann, Mathis, Hoermann, Rudolf, Wittert, Gary, Yeap, Bu B.·2015·Clinical Endocrinology
DOI 10.1111/cen.12664
Open this paper in CoChat — free account

Abstract

Summary: Context: The effects of testosterone treatment on glucose metabolism and other outcomes in men with type 2 diabetes (T2D) and/or the metabolic syndrome are controversial. Objective: To perform a systematic review and meta‐analysis of placebo‐controlled double‐blind randomized controlled clinical trials (RCT) of testosterone treatment in men with T2D and/or the metabolic syndrome. Data sources: A systematic search of RCT s was conducted using Medline, Embase and the Cochrane Register of controlled trials from inception to July 2014 followed by a manual review of the literature. Study selection: Eligible studies were published placebo‐controlled double‐blind RCT s published in English. Data extraction: Two reviewers independently selected studies, determined study quality and extracted outcome and descriptive data. Data synthesis: Of the 112 identified studies, seven RCT s including 833 men were eligible for the meta‐analysis. In studies using a simple linear equation to calculate the homeostatic model assessment of insulin resistance (HOMA 1), testosterone treatment modestly improved insulin resistance, compared to placebo, pooled mean difference (MD) −1·58 [−2·25, −0·91], P < 0·001. The treatment effect was nonsignificant for RCT s using a more stringent computer‐based equation (HOMA 2), MD −0·19 [−0·86, 0·49], P = 0·58). Testosterone treatment did not improve glycaemic (HbA1c) control, MD −0·15 [−0·39, 0·10], P = 0·25, or constitutional symptoms, Aging Male Symptom score, MD −2·49 [−5·81, 0·83], P = 0·14). Conclusions: This meta‐analysis does not support the routine use of testosterone treatment in men with T2D and/or the metabolic syndrome without classical hypogonadism. Additional studies are needed to determine whether hormonal interventions are warranted in selected men with T2D and/or the metabolic syndrome.

Integrity signals

Registry

Crossref · 10.1111/cen.12664

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Controversy remains around whether testosterone therapy affects the risk of cardiovascular events.

    “Though testosterone therapy improves bone mineral density, lean body mass, erectile function, and anemia, there is inconclusive evidence on the benefits of testosterone therapy on cognitive function, energy levels, blood glucose or lipid levels, and controversy remains around whether testosterone therapy affects the risk of cardiovascular events (6-13).”

    From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [11]

  • Testosterone therapy improves bone mineral density, lean body mass, erectile function, and anemia.

    “Though testosterone therapy improves bone mineral density, lean body mass, erectile function, and anemia, there is inconclusive evidence on the benefits of testosterone therapy on cognitive function, energy levels, blood glucose or lipid levels, and controversy remains around whether testosterone therapy affects the risk of cardiovascular events (6-13).”

    From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [11]

  • Evidence is inconclusive on the benefits of testosterone therapy on cognitive function, energy levels, blood glucose or lipid levels.

    “Though testosterone therapy improves bone mineral density, lean body mass, erectile function, and anemia, there is inconclusive evidence on the benefits of testosterone therapy on cognitive function, energy levels, blood glucose or lipid levels, and controversy remains around whether testosterone therapy affects the risk of cardiovascular events (6-13).”

    From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [11]

  • In the RCT by Ng Tang Fui et al. (reference 91), metabolically favourable changes in body composition from testosterone treatment did not augment weight loss-associated improvements in glucose metabolism.

    “Interestingly, in this RCT, 91 the metabolically favourable changes in body composition consequent to testosterone treatment did not augment weight loss-associated improvements in glucose metabolism, consistent with testosterone treatment RCTs that did not incorporate weight loss measures.51,52”

    From Hypogonadism and male obesity: Focus on unresolved questions (2018) · cites this paper as [51]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Grossmann, M., Hoermann, R., Wittert, G., & Yeap, B. B.
Affiliations
  • The University of Melbourne (AU)
  • Royal Adelaide Hospital (AU)
  • The University of Western Australia (AU)
Corresponding author
Grossmann, Mathis
ORCID
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2014-12-29
Volume
83
Issue
3
Pages
344-351
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
DOI
10.1111/cen.12664
OpenAlex
W2078940124
Cited by
139
References
36
Citations by year
2026: 3 · 2025: 6 · 2024: 17 · 2023: 6 · 2022: 10 · 2021: 14 · 2020: 8 · 2019: 10 · 2018: 27 · 2017: 15 · 2016: 10 · 2015: 12
FWCI
1.96
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Clinical Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (University of Western Australia) (submittedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
testosterone replacement therapy, type 2 diabetes, metabolic syndrome, insulin resistance, glucose metabolism, HbA1c, aging male symptoms, hypogonadism, men
MeSH terms
Androgens, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Testosterone, Randomized Controlled Trials as Topic, Treatment Outcome, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review